Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab, plasmapheresis, and combination therapy in hospitalized COVID-19 patients
IRCT20220123053807N1Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of tocilizumab in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Shahid Sadoughi University of Medical Sciences. Primary endpoints: Blood oxygen level, Clinical outcomes and 7 more. Started Jan 2022; status: completed.
02
Drugs
tocilizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on IRCT20220123053807N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220123053807N1.